



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

BIBDATASHEET

CONFIRMATION NO. 9991

Bib Data Sheet

| | | | | |
|-----------------------------|--|--------------|------------------------|---|
| SERIAL NUMBER 10/770,382 | FILING OR 371(c) DATE 02/02/2004 RULE | CLASS 514 | GROUP ART UNIT 1624 | ATTORNEY DOCKET NO. FRAV2003/0002 US NP |
|-----------------------------|--|--------------|------------------------|---|

APPLICANTS

/ Marcel Patek, Tucson, AZ;
/ Anil Nair, Tucson, AZ;
/ Augustin Hittinger, Igny, FRANCE;
/ Conception Nemecek, Thiais, FRANCE;
/ Daniel Bond, Tucson, AZ;
/ Greg Harlow, Boulder, CO;
/ Herve Bouchard, Thiais, FRANCE;
/ Jacques Mauger, Tucson, AZ;
/ Jean-Luc Malleron, Marcoussis, FRANCE;
/ Mark Palermo, Peapack, NJ;
/ Fahad Al-Obeidi, Tucson, AZ;
/ Thomas Faitg, Exton, PA;
/ Hartmut Strobel, Liederbach, GERMANY;
/ Sven Ruf, Floersheim, GERMANY;
/ Kurt Ritter, Frankfurt Am Main, GERMANY;
/ Youssef El-Ahmad, Creteil, FRANCE;
/ Dominique Lesuisse, Montreuil, FRANCE;
/ Didier Benard, Attainville, FRANCE;

** CONTINUING DATA *****

OK This appln claims benefit of 60/468,685 05/07/2003

** FOREIGN APPLICATIONS *****

OK FRANCE 03 01098 01/31/2003

IF REQUIRED, FOREIGN FILING LICENSE GRANTED **
05/03/2004

| | | | | |
|---|---------------------------|------------------------|-----------------------|----------------------------|
| Foreign Priority claimed <input checked="" type="checkbox"/> yes <input type="checkbox"/> no | STATE OR COUNTRY AZ | SHEETS DRAWING 0 | TOTAL CLAIMS 76 | INDEPENDENT CLAIMS 1 |
| 35 USC 119 (a-d) conditions met <input checked="" type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance | | | | |
| Verified and Acknowledged Examiner's Signature <i>Samuel Ruff</i> Initials <i>sdh</i> | | | | |

ADDRESS
5487

TITLE

OK Novel Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors

9/26/07
FILING FEE
RECEIVED

FEES: Authority has been given in Paper
No. _____ to charge/credit DEPOSIT ACCOUNT

| |
|--|
| <input type="checkbox"/> All Fees |
| <input type="checkbox"/> 1.16 Fees (Filing) |
| <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) |